-
Tytuł:
-
Visit-to-visit fasting blood glucose variability and lifetime risk of cardiovascular disease: a prospective study.
-
Autorzy:
-
Bi J; Department of Maternal and Child Health, School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, No.13 Hangkong Road, Wuhan, 430030, China.; Ministry of Education Key Laboratory of Environment and Health, and State Key Laboratory of Environmental Health (Incubating), School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Song L; Department of Maternal and Child Health, School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, No.13 Hangkong Road, Wuhan, 430030, China.; Ministry of Education Key Laboratory of Environment and Health, and State Key Laboratory of Environmental Health (Incubating), School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Wang L; Department of Maternal and Child Health, School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, No.13 Hangkong Road, Wuhan, 430030, China.; Ministry of Education Key Laboratory of Environment and Health, and State Key Laboratory of Environmental Health (Incubating), School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Wu M; Department of Maternal and Child Health, School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, No.13 Hangkong Road, Wuhan, 430030, China.; Ministry of Education Key Laboratory of Environment and Health, and State Key Laboratory of Environmental Health (Incubating), School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Chen S; Department of Cardiology, Kailuan Hospital, North China University of Science and Technology, Tangshan City, China.
Wang Y; Department of Maternal and Child Health, School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, No.13 Hangkong Road, Wuhan, 430030, China.; Ministry of Education Key Laboratory of Environment and Health, and State Key Laboratory of Environmental Health (Incubating), School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Wu S; Department of Cardiology, Kailuan Hospital, North China University of Science and Technology, Tangshan City, China. .
Tian Y; Department of Maternal and Child Health, School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, No.13 Hangkong Road, Wuhan, 430030, China. yaohua_.; Ministry of Education Key Laboratory of Environment and Health, and State Key Laboratory of Environmental Health (Incubating), School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. yaohua_.
-
Źródło:
-
Cardiovascular diabetology [Cardiovasc Diabetol] 2021 Oct 16; Vol. 20 (1), pp. 207. Date of Electronic Publication: 2021 Oct 16.
-
Typ publikacji:
-
Journal Article; Observational Study; Research Support, Non-U.S. Gov't
-
Język:
-
English
-
Imprint Name(s):
-
Original Publication: London : BioMed Central, [2002-
-
MeSH Terms:
-
Office Visits*
Blood Glucose/*metabolism
Cardiovascular Diseases/*blood
Fasting/*blood
Glucose Metabolism Disorders/*blood
Adult ; Age Factors ; Biomarkers/blood ; Cardiovascular Diseases/diagnosis ; Cardiovascular Diseases/epidemiology ; China/epidemiology ; Female ; Glucose Metabolism Disorders/diagnosis ; Glucose Metabolism Disorders/epidemiology ; Heart Disease Risk Factors ; Humans ; Incidence ; Male ; Middle Aged ; Predictive Value of Tests ; Prognosis ; Prospective Studies ; Risk Assessment ; Time Factors
-
References:
-
Circ Res. 2018 Sep 14;123(7):886-904. (PMID: 30355075)
Physiol Genomics. 2008 Jan 17;32(2):254-63. (PMID: 17986523)
Cardiovasc Diabetol. 2020 Sep 22;19(1):144. (PMID: 32962711)
Diabetes Care. 2019 Mar;42(3):486-493. (PMID: 30659073)
Pharmacol Ther. 2012 Jul;135(1):54-70. (PMID: 22484805)
Med Clin North Am. 1998 May;82(3):511-22. (PMID: 9646777)
Diabetes Care. 2017 Nov;40(11):1565-1572. (PMID: 28887409)
Lancet Diabetes Endocrinol. 2019 Mar;7(3):221-230. (PMID: 30115599)
Hypertension. 2017 Sep;70(3):508-514. (PMID: 28716992)
JAMA. 2003 Oct 8;290(14):1884-90. (PMID: 14532317)
Am J Physiol Renal Physiol. 2006 Feb;290(2):F509-16. (PMID: 16189290)
Lancet Diabetes Endocrinol. 2019 May;7(5):385-396. (PMID: 30926258)
Cardiovasc Res. 2011 Jan 1;89(1):119-28. (PMID: 20724307)
J Cell Mol Med. 2017 May;21(5):1024-1032. (PMID: 27957792)
Diabetes Care. 2019 Apr;42(4):674-681. (PMID: 30728222)
J Natl Cancer Inst. 1993 Jun 2;85(11):892-7. (PMID: 8492317)
Stat Med. 2000 Jun 15-30;19(11-12):1495-522. (PMID: 10844714)
FEBS Lett. 2005 May 9;579(12):2541-5. (PMID: 15862287)
JAMA. 2006 Apr 12;295(14):1681-7. (PMID: 16609090)
Circ Res. 2004 Oct 1;95(7):692-9. (PMID: 15345655)
Cardiovasc Diabetol. 2021 Mar 22;20(1):66. (PMID: 33752676)
Oxid Med Cell Longev. 2019 Jun 23;2019:7092151. (PMID: 31341533)
Diabetologia. 2009 May;52(5):952-61. (PMID: 19263033)
Diabetes. 2008 May;57(5):1349-54. (PMID: 18299315)
Atherosclerosis. 2020 Sep;309:16-26. (PMID: 32858395)
Circulation. 2018 Dec 4;138(23):2627-2637. (PMID: 30571256)
Diabetes Care. 2018 Oct;41(10):2187-2194. (PMID: 30082325)
J Am Heart Assoc. 2017 Nov 29;6(12):. (PMID: 29187392)
Lancet. 2009 May 23;373(9677):1765-72. (PMID: 19465231)
Nephrol Dial Transplant. 2017 Apr 1;32(suppl_2):ii13-ii18. (PMID: 28339913)
Stroke. 2013 Sep;44(9):2451-6. (PMID: 23868276)
Circulation. 2019 Sep 10;140(11):e596-e646. (PMID: 30879355)
J Biol Chem. 2000 Dec 8;275(49):38540-6. (PMID: 10988297)
Diabetologia. 2009 Nov;52(11):2288-98. (PMID: 19655124)
Cardiovasc Diabetol. 2019 Nov 9;18(1):147. (PMID: 31706305)
N Engl J Med. 1999 Jun 10;340(23):1801-11. (PMID: 10362825)
BMC Med. 2014 Sep 26;12:165. (PMID: 25255837)
Lancet. 1999 Jan 9;353(9147):89-92. (PMID: 10023892)
Diabetes Care. 2018 Dec;41(12):2579-2585. (PMID: 30305344)
Nat Rev Endocrinol. 2014 May;10(5):293-302. (PMID: 24663222)
Circulation. 2003 Jun 24;107(24):3059-65. (PMID: 12810616)
-
Grant Information:
-
81273083 national natural science foundation of china
-
Contributed Indexing:
-
Keywords: Cardiovascular disease; Fasting blood glucose variability; Lifetime risk
-
Substance Nomenclature:
-
0 (Biomarkers)
0 (Blood Glucose)
-
Entry Date(s):
-
Date Created: 20211017 Date Completed: 20220131 Latest Revision: 20220131
-
Update Code:
-
20240104
-
PubMed Central ID:
-
PMC8520235
-
DOI:
-
10.1186/s12933-021-01397-1
-
PMID:
-
34656122
-
Aims: Previous studies suggested an adverse association between higher fasting blood glucose (FBG) variability and cardiovascular disease (CVD). Lifetime risk provides an absolute risk assessment during the remainder of an individual's life. However, the association between FBG variability and the lifetime risk of CVD is uncertain.
Objective: We aimed to investigate the effect of the visit-to-visit FBG variability on the lifetime risk of CVD.
Methods: This study included participants from the Kailuan Study who did not have CVD at index ages 35, 45, and 55 years. The FBG variability was defined as the coefficient of variation (CV) of three FBG values that were measured during the examination periods of 2006-2007, 2008-2009, and 2010-2011. We used a modified Kaplan-Merrier method to estimate lifetime risk of CVD according to tertiles of FBG variability.
Results: At index age 35 years, the study sample comprised 46,018 participants. During a median follow-up of 7.0 years, 1889 participants developed CVD events. For index age 35 years, participants with high FBG variability had higher lifetime risk of CVD (32.5%; 95% confidence interval [CI]: 28.9-36.1%), compared with intermediate (28.3%; 95% CI: 25.5 -31.1%) and low (26.3%; 95% CI: 23.0-29.5%) FBG variability. We found that higher FBG variability was associated with increased lifetime risk of CVD in men but not women. Similar patterns were observed at index ages 45 and 55 years.
Conclusions: Higher FBG variability was associated with increased lifetime risk of CVD at each index age. Focusing on the FBG variability may provide an insight to the clinical utility for reducing the lifetime risk of CVD.
(© 2021. The Author(s).)
Zaloguj się, aby uzyskać dostęp do pełnego tekstu.
